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ABSTRACT
Hepatic uptake and efflux transporters govern the systemic and
hepatic exposure of many drugs and metabolites. Enalapril is a
pharmacologically inactive prodrug of enalaprilat. Following oral
administration, enalapril is converted to enalaprilat in hepatocytes
and undergoes translocation into the systemic circulation to exert its
pharmacologic effect by inhibiting angiotensin-converting enzyme.
Although the transport proteins governing hepatic uptake of enalapril
and the biliary excretion of enalapril and enalaprilat are well
established, it remains unknown how hepatically derived enalaprilat
translocates across the basolateral membrane into the systemic
circulation. In this study, the role of ATP-binding cassette transport-
ers in the hepatic basolateral efflux of enalaprilat was investigated
using membrane vesicles. ATP-dependent uptake of enalaprilat into
vesicles expressing multidrug resistance–associated protein (MRP) 4
was significantly greater (∼3.8-fold) than in control vesicles. In
contrast, enalaprilat was not transported to a significant extent by
MRP3, and enalapril was not transported by either MRP3 or MRP4.
The functional importance of MRP4 in the basolateral excretion of
derived enalaprilat was evaluated using a novel basolateral efflux
protocol developed in human sandwich-cultured hepatocytes. Under
normal culture conditions, the mean intrinsic basolateral efflux
clearance (CLint,basolateral) of enalaprilat was 0.026 6 0.012 ml/min;
enalaprilat CLint,basolateral was significantly reduced to 0.009 6 0.009
ml/min by pretreatment with the pan-MRP inhibitor MK-571. Results
suggest that hepatically derived enalaprilat is excreted across the
hepatic basolateral membrane byMRP4. Changes in MRP4-mediated
basolateral efflux may alter the systemic concentrations of this active
metabolite, and potentially the efficacy of enalapril.
Introduction
The liver plays a central role in the metabolism, detoxification, and
elimination of endogenous and exogenous compounds. Following up-
take across the basolateral membrane from the blood to the hepatocyte,
metabolism typically results in formation of a more hydrophilic, charged
molecule that can be eliminated either via the bile or across the baso-
lateral membrane into the systemic circulation for renal excretion.
Importantly, following hydrophilic transformation, active efflux pro-
cesses typically are required for the metabolite to exit the liver. In
contrast to biliary excretion, changes in active basolateral efflux
processes (either due to drug-drug interactions or disease-mediated
changes in efflux transporter function) are underappreciated (Köck and
Brouwer, 2012; Konig et al., 2013; Pfeifer et al., 2014). Changes in
basolateral efflux of active metabolites may alter systemic concentrations
and, thus, systemic efficacy/toxicity, and potentially warrant detailed
evaluation during drug development (Köck and Brouwer, 2012; Zamek-
Gliszczynski et al., 2014).
Enalapril is a prodrug transformed in the liver by carboxylesterases
to the active moiety, enalaprilat. Transformation removes the ethylester
from enalapril, adding a negative charge and increasing the potency to
inhibit angiotensin-converting enzyme, thereby lowering blood pressure
and preventing cardiac remodeling and renal dysfunction (Patchett et al.,
1980). Due to the inherent negative charge on the parent drug and added
polarity after metabolism, enalapril and enalaprilat require active
transport processes to cross membranes. Interestingly, the presence of
a diffusional barrier for enalapril and enalaprilat disposition helped lay
the foundation for the identification of transporter-mediated disposition
and clearance mechanisms of charged molecules (Pang et al., 1984,
1998; de Lannoy and Pang, 1986; Schwab et al., 1990). Rat organic
anion transporting polypeptide (OATP) 1a1 and human OATP1B1 are
responsible for the uptake of enalapril into the hepatocyte.
Enalaprilat derived in the liver can be excreted into the bile or
translocated across the basolateral membrane into the systemic cir-
culation (de Lannoy et al., 1993; Pang et al., 1998; Liu et al., 2006).
Although multidrug resistance–associated protein (MRP) 2 is capable
of excreting enalaprilat from the hepatocyte into bile, the majority of
the absorbed dose of enalapril is excreted in the urine as enalaprilat,
which suggests that basolateral efflux of enalaprilat into the systemic
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circulation predominates since enalaprilat appears to be formed only in the
hepatocyte (Tocco et al., 1982; Ulm et al., 1982; de Lannoy et al., 1993).
As the site of action for enalaprilat is in the systemic circulation
(inhibition of angiotensin-converting enzyme), hepatic basolateral efflux
is germane in regulating enalaprilat’s beneficial effects on blood pressure,
cardiac remodeling, and kidney protection. Two proteins that may be able
to transport enalaprilat from the hepatocyte into sinusoidal blood are
MRP3 and MRP4. Substrate specificity profiles and the localization of
MRP3 and MRP4 on the basolateral membrane make them prime
candidates to mediate enalaprilat transport (Gradhand et al., 2008;
Klaassen and Aleksunes, 2010; Chai et al., 2012).
Although enalapril is prescribed extensively in many chronic
diseases, including diabetes, nonalcoholic fatty liver disease, and
renal failure, little is known about how coadministered medications
or disease-associated changes in MRP expression affect enalaprilat
disposition. In addition to specific disease states, disease severity
also can alter basolateral efflux transporter expression (Hardwick
et al., 2011; Hanada et al., 2012; Tsujimoto et al., 2012; Köck et al.,
2013; Yeung et al., 2014). For example, inflammation associated
with nonalcoholic fatty liver disease increases protein expression of
MRPs (e.g., MRP3, MRP4, MRP6) on the basolateral membrane
(Hardwick et al., 2011). Without knowledge of the basolateral
transport process(es) involved in enalaprilat disposition, it is difficult
to accurately predict how disease state alterations and drug-drug in-
teractions may impact systemic concentrations and pharmacological
effects.
This study was designed to determine whether MRP3 and/or MRP4 is
involved in the hepatic basolateral efflux of enalaprilat, and to demonstrate
the impact of MRP inhibition on the hepatic basolateral efflux clearance
of enalaprilat. Enalapril and enalaprilat transport were evaluated in
membrane vesicles prepared from cells expressing either MRP3 or
MRP4. Additionally, a novel experimental protocol was developed
in human sandwich-cultured hepatocytes (SCH) to assess the potential
impact of coadministered medications on enalaprilat basolateral efflux.
Materials and Methods
Enalapril maleate, d5-enalapril, enalaprilat, d5-enalaprilat, taurocholate,
Hanks’ balanced salt solution (HBSS), and Ca2+/Mg2+-free HBSS (Ca2+-free
HBSS) were purchased from Sigma-Aldrich (St. Louis, MO). MK-571 was
purchased from Cayman Chemical Company (Ann Arbor, MI). Rosuvastatin
was purchased from Toronto Research Chemicals (Toronto, Ontario, Canada).
[3H]Taurocholate (1 mCi/ml; .97% purity) and [3H]rosuvastatin (1 mCi/ml;
.97% purity) were purchased from PerkinElmer (Waltham, MA) and American
Radiolabeled Chemicals (St. Louis, MO), respectively. All other chemicals were
commercially available and of the highest grade available.
Human Embryonic Kidney Cell Culture and Overexpression of MRP3
and MRP4. Human MRP3 plasmid [pcDNA3.1(2)-MRP3] and MRP4 plasmid
[pcDNA3.1(+)-MRP4] were kindly provided by Dr. Susan Cole (Queen’s
University, Kingston, Canada) and Dr. Dietrich Keppler (German Cancer
Research Center, Heidelberg, Germany), respectively. Human embryonic
kidney (HEK) 293T cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum in a humidified incubator.
For MRP4, a stable transfected cell line was developed as previously described
(Köck et al., 2013). For MRP3, transient transfection of HEK293T cells with
X-tremeGENE 9 DNA Transfection Reagent (Roche Diagnostics, Mannheim,
Germany) was performed according to the manufacturer’s instructions. Seventy-
two hours after transfection, the cells were harvested. Nontransfected and control
mock-transfected cells were used to generate control membrane vesicles for the
MRP3 and MRP4 assays, respectively. Cells were harvested by trypsinizing and
centrifuging the transporter-overexpressing cells and the respective control cell lines.
The cell pellets were washed in Tris-sucrose buffer (TSB; 250 mM sucrose/50 mM
Tris, pH 7.4) containing 0.25 mM CaCl2. The final cell pellet was overlaid with
10 ml TSB containing 0.25 mM CaCl2 and protease inhibitors (complete Mini
EDTA-free; Roche Diagnostics), snap-frozen in liquid nitrogen, and stored at280°C.
Membrane Vesicle Preparation. Membrane vesicles were prepared for
MRP4, MRP3, and respective controls as described previously (Ghibellini
et al., 2008). In brief, frozen cell pellets were thawed, resuspended in TSB, and
exploded by N2 cavitation (300 psi, 5 minutes). After addition of EDTA
(1 mM), the suspension was centrifuged (800  g, 10 minutes, 4°C) and the
supernatant was collected. The pellet was resuspended in TSB with 0.5 mM
EDTA and centrifuged (800  g, 10 minutes, 4°C). The resulting supernatants
were overlaid over 35% (w/w) sucrose/50 mM Tris buffer in a high-speed
centrifuge tube. After centrifugation (100,000  g, 90 minutes, 4°C), the
interphase was collected and added to a new high-speed centrifuge tube with
25 mM sucrose/50 mM Tris buffer. After additional centrifugation (100,000  g,
45 minutes, 4°C), the pellet was resuspended in 1 ml TSB. The suspension
was added to a high-speed centrifuge tube and centrifuged (100,000  g,
20 minutes, 4°C). The supernatant was discarded and the pellet was resuspended
in TSB. Subsequently, the suspension was homogenized using a 27-gauge needle
(15 strokes). The membrane vesicle suspension was divided into aliquots, snap-
frozen in liquid nitrogen, and stored at 280°C until use. Successful transfection
was confirmed via Western blotting and transport of radiolabeled prototypic
probes as described previously (Köck et al., 2013).
Membrane Vesicle Assay. Membrane vesicles (10 mg) were incubated at
37°C with enalapril or enalaprilat (100 mM) with and without MK-571 (50 mM)
in TSB containing MgCl2 (10 mM), creatine phosphate (10 mM), creatine
kinase (100 mg/ml), and ATP (4 mM) in a final volume of 50 ml. Enalapril,
enalaprilat, and MK-571 stock solutions were prepared in TSB or 100%
dimethylsulfoxide with a resulting dimethylsulfoxide final concentration of
less than 1% in the total incubation volume. ATP was replaced by AMP (4 mM)
for control reactions. At least three separate experiments in triplicate were
performed for all incubations, unless otherwise noted. After incubation for
5 minutes, the reactions were stopped by addition of 800 ml of ice-cold TSB and
immediately filtered through glass fiber filters (Pall Life Sciences, Port
Washington, NY) presoaked in 3 mM reduced glutathione/10 mM dithiothreitol
in TSB overnight. Filters were washed three times with ice-cold TSB. Filters
were air dried and dissolved in 1 ml of pure high-performance liquid
chromatography methanol containing d5-enalapril and d5-enalaprilat for liquid
chromatography–tandem mass spectrometry (LC-MS/MS) analysis. ATP-
dependent uptake was calculated as the difference in uptake in the presence
of AMP and ATP. MRP-dependent substrate transport was calculated by sub-
tracting ATP-dependent uptake in control membrane vesicles from uptake in
membrane vesicles prepared from MRP3- or MRP4-expressing cells.
Sandwich-Cultured Hepatocyte Isolation and Culture. Human hepato-
cytes from three donors were kindly provided by Life Technologies (Research
Triangle Park, NC) and Triangle Research Laboratories (Research Triangle
Park, NC), and cultured as previously described (Swift et al., 2010). Hepatocyte
donors included three Caucasian men ranging in age from 20 to 48 years with
a body mass index of 19–31 kg/m2. In brief, freshly isolated human hepatocytes
were seeded in six-well BioCoat plates (BD Biosciences, San Jose, CA) at
a density of 1.5  106 cells/well. Hepatocytes were overlaid with Matrigel
basement membrane matrix (BD Biosciences) and maintained as described
previously (Swift et al., 2010).
Sandwich-Cultured Hepatocyte Uptake and Biliary Excretion Studies.
Determination of the uptake and biliary excretion of probe substrates in human
SCH has been described previously (Abe et al., 2009). Slight modifications
were made to allow determination of enalapril and enalaprilat uptake,
formation, and excretion. In brief, human SCH were washed twice with 2 ml
of warm Ca2+-containing standard HBSS (cells + bile) or Ca2+-free HBSS
(cells) and incubated with 1.5 ml of the same buffer for 10 minutes at 37°C
containing either [3H]taurocholate (1 mM; 100 nCi/ml), [3H]rosuvastatin
(1 mM; 100 nCi/ml), or enalapril (5 mM). After 10 minutes, cells were washed
three times with ice-cold standard HBSS and lysed with either 0.5% Triton
X-100 in phosphate-buffered saline (for [3H]taurocholate and [3H]rosuvastatin
analysis) or pure high-performance liquid chromatography grade methanol
containing internal standards (for enalapril and enalaprilat analysis). Radioac-
tivity in cell lysates was quantified by liquid scintillation spectroscopy (Packard
Tri-Carb; PerkinElmer). Enalapril and enalaprilat were quantified in cell lysates
using LC-MS/MS. Accumulation of taurocholate, rosuvastatin, enalapril, and
enalaprilat in cells and cells + bile was normalized to protein determined using a
BCA protein assay (Pierce Chemical, Rockford, IL). The biliary excretion index
(BEI; % and in vitro biliary clearance (CLbiliary; ml/min/kg) were calculated using
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B-CLEAR technology (Qualyst Transporter Solutions, LCC, Durham, NC) based
on the following equations:
BEI ¼ Accumulationcellsþbile 2 Accumulationcells
Accumulationcellsþbile
CLbiliary ¼ Accumulationcellsþbile 2 AccumulationcellsAUCmedium 02T
where the area under the curve in the medium from time 0 to T (AUCmedium 0-T)
represents the product of the incubation time (T) and the initial taurocholate,
rosuvastatin, or enalapril concentration in the medium. CLbiliary units were
converted to ml/min/kg body weight based on previously reported values for
human protein content in liver tissue (90 mg/g liver weight) and liver weight
(25.7 g/kg body weight) (Davies and Morris, 1993).
Sandwich-Cultured Hepatocyte Basolateral Efflux Studies. On day 6 of
culture, human SCH were loaded with enalapril for 60 minutes at 37°C with
2 ml/well of standard HBSS containing 5 mM enalapril with and without 25 mM
MK-571. The buffer was removed and the cells were washed two times with
warm, standard HBSS At this point, 1 ml of methanol containing internal
standards was added to one set of each SCH preparation (designated as “pre-
efflux SCH”) to assess intracellular accumulation of enalapril and derived
enalaprilat. Enalaprilat efflux was initiated in the other set of SCH by adding
2 ml of fresh, warm, standard HBSS without enalapril followed by incubation for
30 minutes at 37°C. Aliquots (100 ml) of efflux buffer were taken at 5, 10, and
30 minutes to determine the amount of enalaprilat translocated into the efflux
buffer. At 30 minutes, the buffer was aspirated and the cells were washed three
times with ice-cold buffer. Post-efflux SCH were lysed in 1 ml of ice-cold
methanol containing internal standards. Enalapril and enalaprilat were quan-
tified in efflux buffer, and pre- and post-efflux SCH lysates, by LC-MS/MS
(Fig. 1; Table 1). Intracellular enalaprilat concentrations pre- and post-efflux
were calculated by dividing the total mass present in the cell lysate by the
estimated hepatocyte volume reported previously as 7.69 ml/mg protein,
assuming 1 mg of cellular protein per well (Lee and Brouwer, 2010). Intrinsic
basolateral efflux clearance of enalaprilat (CLint,basolateral) was calculated ac-
cording to the following equation,
CLint;basolateral ¼ XEfflux Buffer t1 → t2AUCCell t1 → t2
where XEfflux Buffer was the cumulative amount of enalaprilat excreted from the
cell over the efflux period (t1→t2), assuming that biliary excretion and flux from
the bile compartment into the efflux buffer were negligible; AUCCell represented
the log-trapezoidal exposure of intracellular enalaprilat over the efflux period.
LC-MS/MS Analysis. Enalapril and enalaprilat were quantified by LC-MS/MS
using an Applied Biosystems (Foster City, CA) API 4000 triple quadrupole
mass spectrometer equipped with a TurboV ion source (Applied Biosystems,
Foster City, CA), a Shimadzu solvent delivery system (Columbia, MD), and
a thermostatted CTC PAL autosampler (Leap Technologies, Carborro, NC).
Tuning, operation, integration, and data analysis were carried out in positive
mode using multiple reaction monitoring (Analyst software v.1.4.1; Applied
Biosystems). Following an 8ml injection onto a Varian Pursuit 3 PFP column
(50  2 mm, 3 mm particle size; Santa Clara, CA), analytes were eluted via
reverse-phase gradient at 0.30 ml/min. Mobile phase A consisted of water and
0.1% formic acid; mobile phase B consisted of methanol with 0.1% formic
acid. The initial condition was 80% aqueous, reaching 50% methanol at
1 minute and 97% methanol at 4 minutes. After a 0.4-minute hold at 97%
methanol, the mobile phase returned to initial conditions at 4.5 minutes. The
total run time, including re-equilibration, was 5 minutes. The specific analytes
were monitored as follows: enalapril (377.0 → 234.0), d5-enalapril (internal
standard, 382.0 → 239.0), enalaprilat (349.0 → 206.0), and d5-enalaprilat
(internal standard, 354.0 → 211.0). Duplicate 8-point calibration curves for
both enalapril and enalaprilat (0.075–375 nM) were constructed using the peak
area ratio of analyte to deuterated internal standard. In an attempt to mimic the
various matrix components (lipids, salts, proteins), separate calibration curves
Fig. 1. (A) Scheme depicting efflux studies in human SCH de-
scribing the loading and efflux phases (see Materials and Methods
for a detailed description). (B) Average enalaprilat cellular accu-
mulation (red squares) and mass excreted into the efflux buffer (blue
diamonds) observed during the efflux phase in a representative
human SCH preparation under control conditions according to the
scheme depicted in (A) (mean 6 S.D. of triplicate measurements).
The green dotted line indicates the presumed cellular accumulation
of enalaprilat during the loading phase. Enalaprilat cellular exposure
during the efflux phase (AUCcell 0→30; red trapezoid) was calculated
as the log-trapezoidal product of intracellular enalaprilat mass
divided by the estimated intracellular volume and time. The mass
of enalaprilat excreted into the efflux buffer (XEfflux Buffer) was
determined by multiplying the concentration measured in the buffer
by the buffer volume.
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were constructed with blank matrix from each of the different sample types
(i.e., vesicles, cell lysate, and buffer).
Data Analysis. Data are presented as the mean 6 S.D. unless otherwise
noted. A two-sided Student’s t-test was used to determine significant differences;
in all cases, P , 0.05 was considered significant.
Results
ATP-Dependent Transport of Enalapril and Enalaprilat by
Membrane Vesicles Prepared from MRP3- and MRP4-Expressing
Cells. Prior to enalapril and enalaprilat uptake studies, each batch of
membrane vesicles was characterized for protein expression and transport
activity of probe substrates as described previously (Köck et al., 2013).
ATP-dependent uptake of enalapril and enalaprilat by membrane vesicles
prepared from MRP3- and MRP4-expressing cells was determined in
vesicles incubated with enalapril or enalaprilat (Fig. 2). ATP-dependent
uptake of enalapril was not significantly different in membrane vesicles
prepared from MRP3- or MRP4-expressing cells compared with the
respective control (Fig. 2A). Although ATP-dependent enalaprilat uptake
was not significantly different between control and MRP3-expressing
vesicles, statistically significant MRP4-dependent uptake was observed
(277 6 194 pmol/mg protein/min); the uptake rate of enalaprilat was
3826 133% greater in vesicles from MRP4-expressing cells compared
with mock-transfected control cells. MRP4-mediated enalaprilat trans-
port was investigated in the presence of the prototypical MRP inhibitor
MK-571, at a concentration of 50 mM. MK-571 significantly inhibited
enalaprilat transport by 836 30% (Fig. 3). MRP4-mediated enalaprilat
transport was modestly inhibited by rosuvastatin, but differences were
not statistically significant (data not shown).
Human SCH Uptake and Biliary Excretion Studies. Studies were
conducted in human SCH to determine the total and cellular accumulation,
biliary excretion index, and CLbiliary of the positive controls, taurocholate
and rosuvastatin. Following a 10-minute incubation of human SCH with
1 mM [3H]taurocholate or 1 mM [3H]rosuvastatin, total accumulation
(cells + bile), cellular accumulation (cells), and biliary excretion index
(BEI) of taurocholate and rosuvastatin were determined (Fig. 4A). BEI
and CLbiliary values for taurocholate and rosuvastatin were 81 6 9%
and 22.4 6 4.6 ml/min/kg body weight, and 39 6 7% and 6.4 6
1.3 ml/min/kg body weight, respectively, indicating robust biliary clearance
of these compounds (Abe et al., 2009). Additionally, total accumulation,
cellular accumulation, and the BEI of enalapril were measured. Following
a 10-minute incubation of human SCH with enalapril, a higher total
accumulation and cellular accumulation of derived enalaprilat compared
with enalapril was observed (Fig. 4B), suggesting rapid and extensive
conversion of enalapril to enalaprilat. CLbiliary of parent enalapril was
negligible in human SCH (0.02 6 0.01 ml/min/kg body weight; mean 6
S.D., n = 2 in triplicate). Biliary excretion of derived enalaprilat was not
quantifiable in human SCH after a 10-minute incubation period.
Human Sandwich-Cultured Hepatocyte Basolateral Efflux
Studies. Basolateral efflux clearance of enalaprilat was assessed in
human SCH. Following the 60-minute loading phase with and without
MK-571, accumulation of enalapril within the hepatocytes was
negligible due to rapid conversion to enalaprilat. Pre-efflux cellular
accumulation of derived enalaprilat was decreased when MK-571
was coincubated with enalapril during the loading phase, suggesting
inhibition of enalapril uptake processes (Table 1). Correspondingly,
with decreased intracellular concentrations over the entire efflux period,
the total mass available for efflux across the basolateral membrane in
human SCH coincubated with MK-571 also decreased compared with
control. Therefore, intrinsic basolateral efflux clearance was calculated
by dividing the total mass effluxed across the basolateral membrane
by the calculated enalaprilat area under the cellular concentration-time
curve (Table 1). MK-571 significantly decreased intrinsic basolateral
efflux clearance (Fig. 5; Table 1). Enalaprilat intrinsic basolateral efflux
clearance was modestly inhibited by rosuvastatin, but differences were
not statistically significant (data not shown).
Discussion
The present study was designed to determine the involvement of
MRP3 and/or MRP4 in the basolateral efflux of enalapril and
enalaprilat. Using membrane vesicles, MRP3 did not appear to transport
either enalapril or enalaprilat. Enalaprilat, but not enalapril, was ac-
tively transported by MRP4. To confirm MRP4-mediated transport of
enalaprilat, inhibition of uptake by the pan-MRP prototypical inhibitor,
MK-571, was evaluated (Köck et al., 2013; Pfeifer et al., 2013b).
Indeed, potent inhibition by MK-571 (83%) was observed.
Studies were conducted in human SCH to assess the basolateral
efflux of derived enalaprilat in intact hepatocytes. First, the accumu-
lation and biliary excretion of taurocholate and rosuvastatin, two
prototypical positive controls that are excreted into bile, were measured
to confirm the functionality of the basolateral uptake and canalicular
transport processes in the SCH used in this study. Indeed, human SCH
exhibited extensive hepatic uptake and biliary clearance of both
taurocholate and rosuvastatin. Biliary excretion of enalaprilat was
negligible following a 10-minute incubation with enalapril in human
SCH (Fig. 4A). Cellular accumulation of preformed enalaprilat in rat
SCH was negligible (data not shown), consistent with previously
published data demonstrating a diffusional barrier for hepatic uptake of
enalaprilat (de Lannoy et al., 1993). Taken together, these data suggest
that the basolateral translocation of enalaprilat into the efflux buffer
appears to be the only route of excretion of derived enalaprilat in SCH,
and that reuptake of enalaprilat does not occur to any measureable
extent. Therefore, basolateral excretion of derived enalaprilat was
determined in human SCH in the presence and absence of MK-571 to
assess the impact of MRP-mediated inhibition of basolateral efflux.
Fig. 2. Transport of enalapril and enalaprilat by
MRP3 and MRP4. Uptake of enalapril (100 mM)
(A) and enalaprilat (100 mM) (B) into membrane
vesicles prepared from HEK293T cells express-
ing MRP3 or MRP4 (10 mg; solid bars) or mock-
transfected controls (10 mg; open bars) was
determined after a 5-minute incubation in the
presence of ATP or AMP. Data are presented as
the mean 6 S.D. ATP-dependent uptake into
vesicles was determined from three (MRP3)
or four (MRP4) independent experiments per-
formed in triplicate; *P , 0.05 versus respective
control.
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Interestingly, the relative extent of inhibition of basolateral efflux
clearance of enalaprilat in human SCH was similar to that observed in
membrane vesicles prepared from HEK293T cells expressing MRP4
(Figs. 3 and 5); MK-571 inhibition of uptake into membrane vesicles
and intrinsic basolateral efflux clearance in human SCH were 83% and
67%, respectively. This finding should be interpreted cautiously because
MK-571 is a nonselective MRP inhibitor, and other MRP transporters
in addition to MRP4 could contribute to the basolateral efflux of enalaprilat
in human hepatocytes.
Following intestinal absorption of enalapril, the predominant route
of excretion is presumed to be hepatic metabolism to enalaprilat fol-
lowed by basolateral efflux of enalaprilat into the systemic circulation
and subsequent renal excretion (Ulm, 1983). In isolated perfused rat
livers, the magnitude of the basolateral efflux clearance of derived
enalaprilat was at least 2-fold greater than biliary clearance (de Lannoy
et al., 1993). These preclinical data are consistent with human data
indicating that .90% of orally absorbed enalapril is recovered in the
urine as enalaprilat (Ulm, 1983). Given this disposition profile, where
enalaprilat is excreted preferentially from the liver into the systemic
circulation followed by renal excretion, inhibition of MRP4 transport
would be expected to decrease systemic enalaprilat concentrations
in vivo and the resulting pharmacodynamic effect. The converse also
may be true, where increased MRP4 protein expression due to disease
[e.g., nonalcoholic steatohepatitis (Hardwick et al., 2011)] would be
expected to increase systemic concentrations.
In the present study, a novel basolateral efflux protocol was de-
veloped in human SCH to elucidate the impact of basolateral efflux
transporter inhibition (e.g., MRP4) on enalaprilat disposition. Following
confirmation of the role of MRP4 in enalaprilat transport, basolateral
efflux clearance was calculated by dividing the amount of enalaprilat
translocated from the hepatocyte into the efflux buffer by the estimated
exposure of intracellular enalaprilat. Accurate determination of baso-
lateral efflux using this method assumes that 1) biliary excretion of the
compound is negligible; 2) the compound, once effluxed from the
hepatocyte, does not re-enter the hepatocyte (i.e., the metabolite must
be hepatically derived); and 3) any further conversion from parent to
metabolite after the loading phase is insignificant. Data presented in this
manuscript suggest that these assumptions are true in the SCH model
under the described study conditions. Enalapril and enalaprilat biliary
excretion was minimal in human SCH (Fig. 4); thus, potential flux
during the efflux phase from the bile canaliculi of SCH into the medium
would be negligible. Pilot studies in rat SCH indicated that preformed
enalaprilat does not re-enter the hepatocyte (data not shown), consistent
with previous reports that enalaprilat is not transported by rat Oatp1a1
(Pang et al., 1998). Although rat Oatp1a1 and human OATP1B1 are not
completely homologous, pharmacophore modeling indicated that sub-
strates for these transporters have similar structural moieties (Chang
et al., 2005). Finally, the concentration of enalapril in the hepatocyte
was very low compared with enalaprilat following both the loading
phase and the efflux phase in the human SCH protocol, indicating rapid
conversion of enalapril to enalaprilat in the hepatocyte. Alternatively, to
assess the impact of delayed conversion of parent to metabolite, the
relative concentration of parent to metabolite after the loading phase
should be assessed. If the amount of parent left in the cell following the
loading phase is greater than 10% of the amount of generated metabolite,
conversion during the efflux phase may require further investigation or
optimization of the loading protocol. If these assumptions are violated,
the interplay between uptake, metabolism, basolateral efflux, and
biliary excretion would need to be deconvoluted using mathematical
modeling.
Although inhibition of enalapril uptake would not impact the results
of the current study design, it should be noted that enalaprilat cellular
concentrations were greatly decreased in human SCH treated concom-
itantly with MK-571, likely due to inhibition of OATP1B1-mediated
uptake of enalapril into hepatocytes. MK-571 is a potent inhibitor
(IC50 = 0.3 mM) of OATP1B1 (Yamazaki et al., 2005). Importantly,
failing to account for decreased uptake by direct measurement of cellular
concentrations prior to initiation of the efflux phase may result in over-
estimation of basolateral efflux inhibition.
Fig. 3. Effect of MK-571 on MRP4-mediated enalaprilat transport. Membrane
vesicles prepared from MRP4-expressing HEK293T cells were incubated with
enalaprilat (100 mM) for 5 minutes with and without MK-571 (50 mM). MRP4-
dependent, ATP-dependent uptake was calculated and normalized to transport in
MRP4 vesicles in the absence of MK-571. Data are presented as the mean 6 S.D. of
three independent experiments performed in triplicate; *P , 0.05 vehicle control
versus MK-571.
Fig. 4. Disposition of taurocholate and rosuva-
statin (A) as well as enalapril and derived enalaprilat
(B) in human SCH. Accumulation of taurocholate,
rosuvastatin, enalapril, and enalaprilat in cells + bile
(black bars) and cells (white bars) in human SCH
was measured following a 10-minute incubation
with [3H]taurocholate (1 mM), [3H]rosuvastatin
(1 mM), or enalapril (5 mM). The BEI was calcu-
lated as detailed in Materials and Methods; BEI
values for enalapril and enalaprilat were negligible.
Data represent the mean 6 S.D. of triplicate mea-
surements in three independent hepatocyte prep-
arations for taurocholate and rosuvastatin, or
triplicate measurements in two independent hepa-
tocyte preparations for enalapril and enalaprilat.
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Results suggest that altered MRP4 function may modulate systemic
enalaprilat concentrations and thus enalapril efficacy in vivo. Our
group recently identified many drugs as potent MRP4 inhibitors that
are commonly coadministered in patients with metabolic disease or
hypertension (Köck et al., 2013). In addition to comedications,
concomitant genetic variation or disease states may further influence
enalapril and enalaprilat pharmacokinetics and pharmacodynamics.
Interestingly, genetic variation resulting in reduced OATP1B1 func-
tion increased enalapril and decreased enalaprilat systemic concen-
trations, which may lead to decreased systemic pharmacologic activity
(Tian et al., 2011). Similarly, patients with inflammatory liver disease
(e.g., nonalcoholic steatohepatitis) have decreased OATP and in-
creased MRP4 expression (Fisher et al., 2009; Lake et al., 2011).
These changes in transporter expression together with frequent co-
administration of potent MRP4 inhibitors [i.e., glyburide, fluoxetine,
furosemide, simvastatin (Köck et al., 2013; Morgan et al., 2013)] may
unpredictably alter hepatic and systemic concentrations of drugs/
metabolites that are transported in a manner similar to enalapril/
enalaprilat, potentially leading to therapeutic failure or unexpected
toxicity. Depending on the culture conditions, MRP4 has been shown to
be upregulated in SCH from various species over the culture period
(Tchaparian et al., 2011; Noel et al., 2013). Although this does not
affect the inhibition profile of MK-571, careful evaluation of factors that
alter protein expression in vitro should be considered before data are
extrapolated from SCH to in vivo.
Human SCH have been used to mechanistically evaluate hepatocyte
vectorial transport and reveal the relative contribution of basolateral
versus biliary efflux to overall clearance. Recently, Pfeifer et al.
(2013a,b) and Matsunaga et al. (2014) demonstrated the importance of
the interplay between basolateral and canalicular efflux in the systemic
and hepatic disposition of rosuvastatin and mycophenolic acid glu-
curonide, respectively. Extensive biliary excretion of rosuvastatin and
mycophenolic acid glucuronide required mathematical modeling to
deconvolute the contribution of basolateral versus canalicular trans-
port. In contrast, enalapril/enalaprilat exhibited minimal biliary excre-
tion, allowing direct measurement of basolateral efflux in the present
Fig. 5. Effect of MK-571 on the intrinsic basolateral efflux clearance of enalaprilat
in human sandwich-cultured hepatocytes. CLint,basolateral of enalaprilat was calculated
as described in Materials and Methods. Clearance values are expressed as a
percentage of vehicle-treated control. Data are presented as the mean 6 S.D. of
three independent experiments performed in triplicate; *P , 0.05 vehicle control
versus MK-571.
TABLE 1
Parameters describing hepatically derived enalaprilat disposition in human SCH
Human SCH were incubated with 5 mM enalapril with and without MK-571 (25 mM) for 60 minutes. Enalapril and enalaprilat concentrations in the post-efflux
medium, and in hepatocytes pre- and post-efflux, were quantified as described in Materials and Methods. Data are presented as the mean 6 S.D.; n = 3 independent
hepatocyte preparations performed in triplicate.
Kinetic Parameters Enalapril (5 mM) Control Enalapril (5 mM) + MK-571 (25 mM)
Pre-efflux
Pre-efflux enalaprilat cellular concentration (pmol/ml)
Liver 1 25.5 6 2.5 6.9 6 0.6
Liver 2 5.5 6 0.3 3.0 6 0.1
Liver 3 6.5 6 0.7 2.0 6 0.2
Mean 12.5 6 11.3 4.0 6 2.6
Post-efflux
Post-efflux enalaprilat cellular concentration (pmol/ml)
Liver 1 20.4 6 1.7 5.2 6 0.2
Liver 2 5.2 6 0.6 3.1 6 0.2
Liver 3 6.7 6 0.8 2.4 6 0.1
Mean 10.8 6 8.4 3.6 6 1.5
Mass enalaprilat excreted into efflux buffer
(XEfflux Buffer 0→30, pmol)
Liver 1 16.9 6 1.5 0.8 6 1.3
Liver 2 2.3a 0.4 6 0.7
Liver 3 7.5 6 0.6 1.3 6 0.5
Mean 8.9 6 7.4 0.8 6 0.4
Cellular enalaprilat exposure (AUCCell 0→30, pmol×min/ml)
Liver 1 684 6 16.9 180 6 3.2
Liver 2 160 6 13.6 91.3 6 3.4
Liver 3 199 6 16.2 65.4 6 4.3
Mean 348 6 293 112 6 60.4
Basolateral enalaprilat clearance (CLint, basolateral, ml/min)
Liver 1 0.024 6 0.001 0.004 6 0.004
Liver 2 0.014a 0.004 6 0.007
Liver 3 0.037 6 0.002 0.019 6 0.008
Mean 0.026 6 0.012 0.009 6 0.009 *
aValue imputed due to analytical error as the difference in enalaprilat intracellular concentration pre- versus post-efflux, assuming a cellular volume of 7.69 ml/mg
protein.
*P , 0.05 vehicle control versus MK-571.
1572 Ferslew et al.
studies. These reports demonstrate that altered hepatic transport may
result in modulation of both hepatic and systemic concentrations of
drugs and derived metabolites. In fact, inhibition of hepatic uptake and
biliary excretion of mycophenolic acid glucuronide, which disrupts
enterohepatic recirculation of the parent mycophenolic acid, is postulated
as the mechanism behind decreased systemic exposure to mycophenolic
acid during coadministration with cyclosporine in transplant patients
(Pou et al., 2001; Matsunaga et al., 2014). Additionally, investigation of
rosuvastatin disposition in human SCH and isolated perfused rat livers
revealed that basolateral and canalicular efflux clearances were approx-
imately equal (Pfeifer et al., 2013a,b). This finding demonstrates that,
although rosuvastatin is excreted primarily as unchanged drug in the
feces, basolateral efflux in concert with canalicular efflux are key deter-
minants of rosuvastatin overall disposition, and may impact pharmaco-
logic efficacy and/or toxicity. These examples, together with the present
study, illustrate the importance of hepatic basolateral and canalicular
efflux processes in determining both the pharmacokinetic and pharmaco-/
toxicodynamic profile of drugs and their metabolites.
In summary, enalaprilat, the active metabolite of enalapril, is ef-
fluxed across the basolateral membrane of hepatocytes by MRP4.
MRP4 transport may be inhibited by concomitantly administered
drugs (Hasegawa et al., 2007; El-Sheikh et al., 2013; Fukuda et al.,
2013). This work highlights the significance of active basolateral
efflux in the therapeutic efficacy of active metabolites derived in the
liver and excreted into the systemic circulation. SCH represent a
robust model to study the interplay between basolateral and canalic-
ular efflux. Further studies are required to understand the mechanistic
basis for preferential basolateral or biliary efflux of compounds, and
fully appreciate the consequences on the systemic and hepatic action
of active/toxic metabolites.
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